多中心多国Horizon 2020 MEDIRAD项目中分化型甲状腺癌患者接受放射性碘治疗后的正常器官剂量测定
该多中心研究纳入四个中心的105例分化型甲状腺癌患者,给予固定活度1.1或3.7 GBq的Na[131I]I,采用rhTSH刺激或甲状腺激素撤除,按标准化方案行SPECT(/CT)显像和剂量测定。结果显示各中心唾液腺和全身吸收剂量差异较大,作者认为需个体化剂量测定,并表明达到最低采集和剂量测定标准后数据可跨中心汇总。
要点
- 四个中心共招募105例分化型甲状腺癌患者,给予1.1或3.7 GBq的Na[131I]I。
- 中心1、2、3、4唾液腺每单位给药活度中位吸收剂量分别为0.44、0.14、0.05、0.16 mGy/MBq。
- 1.1与3.7 GBq组全身中位吸收剂量分别为0.05 Gy与0.16 Gy。
核心结论
- 分化型甲状腺癌患者接受Na[131I]I治疗后正常器官剂量差异较大,作者认为凸显了个体化剂量测定的必要性。
- 作者认为若达到采集和剂量测定方案的最低标准,数据可从多中心汇总。
研究设计与样本
- 多国多中心临床研究,患者来自四个中心,共招募105例。
- 患者接受固定活度1.1或3.7 GBq的Na[131I]I,采用rhTSH刺激或甲状腺激素撤除,按当地方案执行。
- 采用标准化采集和重建方案在可变时间点行SPECT(/CT)显像,收集全身滞留数据,由两个剂量测定中心完成正常器官剂量测定并汇总结果。
主要发现
- 中心1、2、3、4唾液腺每单位给药活度中位吸收剂量分别为0.44、0.14、0.05、0.16 mGy/MBq。
- 1.1 GBq组与3.7 GBq组全身中位吸收剂量分别为0.05 Gy与0.16 Gy。
- 中心1、2、3、4全身每单位给药活度中位吸收剂量分别为0.04、0.05、0.04、0.04 mGy/MBq。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[131I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data in a multi-centre setting requires standardised quantitative imaging and dosimetry. A multi-national, multi-centre clinical study was performed to assess absorbed doses delivered to normal organs for differentiated thyroid cancer patients treated with Na[131I]I. METHODS: Patients were enrolled in four centres and administered fixed activities of 1.1 or 3.7 GBq of Na[131I]I using rhTSH stimulation or under thyroid hormone withdrawal according to local protocols. Patients were imaged using SPECT(/CT) at variable imaging time-points following standardised acquisition and reconstruction protocols. Whole-body retention data were collected. Dosimetry for normal organs was performed at two dosimetry centres and results collated. RESULTS: One hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16 mGy/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7 GBq were 0.05 Gy and 0.16 Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04 mGy/MBq were calculated for centre 1, 2, 3 and 4, respectively. CONCLUSIONS: A wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[131I]I, highlighting the necessity for individualised dosimetry. The results show that data may be collated from multiple centres if minimum standards for the acquisition and dosimetry protocols can be achieved.
引用
- Taprogge J, Vergara-Gil A, Leek F, et al. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project. Eur J Nucl Med Mol Imaging. 2023. PMID: 37300572. doi:10.1007/s00259-023-06295-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。